Preparation method and application of intelligent nano regulator for tumor photoimmunotherapy
By preparing the intelligent nano-regulator TCF-PR848 NPs, endoplasmic reticulum stress was guided by the tumor microacidic environment and light irradiation to promote R848 release and DC cell maturation, thus solving the problem of immunosuppression in the tumor microenvironment and achieving a stronger tumor immune response and long-term anti-tumor effect.
Patent Information
- Application Number
- CN202511245873.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-02
- Publication Date
- 2025-12-05
AI Technical Summary
The immunosuppressive properties of existing tumor microenvironments limit the effectiveness of immunotherapy alone, and the poor bioavailability of TLR immunomodulators such as R848 hinders their distribution in tumors, resulting in insufficient immune responses to suppress the growth of residual cells after tumor ablation.
The intelligent nano-regulator TCF-PR848 NPs are co-assembled with pH-sensitive R848 modified with side chains, polyethylene glycol polycarbonate amphiphilic polymer, and small molecule photosensitizer TCy5-Ph-3F. The tumor microacidic environment promotes the release of R848, and combined with light-guided endoplasmic reticulum stress, it promotes the release of immune damage-related molecular patterns and DC cell maturation.
It achieved a stronger immune response, improved dendritic cell maturation, enhanced tumor targeting and reactive oxygen species production, and ensured long-term effective anti-tumor effects.
Smart Images

Figure CN121064466A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the technical field of fine chemical industry, and particularly relates to preparation of an intelligent nano-regulator for tumor photoimmunotherapy and anti-tumor treatment application. The nano-regulator is co-assembled from an amphiphilic polymer and a small molecule photosensitizer. The amphiphilic polymer modifies biotin and Resiquimod (R848). Biotin enables the nano to have an active targeting tumor ability, and the nano causes endoplasmic reticulum stress under light irradiation. In addition, the tumor micro-acidic environment promotes the release of R848, and both of them synergistically promote the maturation of dendritic cells (DCs), so that the host obtains strong immune ability and has long-term anti-tumor activity. BACKGROUND
[0002] Cancer immunotherapy has been proven to be a promising treatment by training or enhancing the host immune response to selectively combat residual tumors and circulating tumor cells. However, the overwhelming immunosuppressive characteristics in the tumor microenvironment (TME), including the accumulation of heterogeneous immunosuppressive cells in the TME, such as myeloid-derived suppressor cells, M2 macrophages or regulatory T cells, severely limit the therapeutic effect of immunotherapy alone. The low efficiency and low specificity of the immune response have led to immune-related adverse events of immunogenic cell death (ICD), which also hinders its widespread application. It is still an urgent desire to improve the efficacy and specificity of ICD therapy. Previous studies have shown that ICD therapy combined with other methods such as chemotherapy, radiotherapy, photodynamic therapy (PDT), photothermal therapy, etc. can significantly enhance the anti-tumor response of tumor immunotherapy. Among them, phototherapy including photodynamic therapy relies on the accumulation of photosensitizers in tumors to absorb external light energy and convert it into excess singlet oxygen to kill cancer cells. In addition to the direct tumor killing effect, in recent years, PDT has also been found to promote anti-tumor immune responses to produce tumor-associated antigens from tumor cell residues, thereby enhancing the ICD response of anti-tumor immunotherapy. However, the immune response generated by single PDT is usually insufficient to inhibit the growth of residual tumor cells after tumor ablation. The immunosuppressive tumor microenvironment still hinders the successful application of these combined strategies.
[0003] Resiquimod (R848), as a toll-like receptor (TLR) 7 / 8 agonist, has been approved by FDA as an immunomodulator for clinical treatment of skin cancer and advanced leukemia. R848 can stimulate dendritic cell (DC) maturation, reverse effector T cell senescence, and thus amplify the immune response triggered by ICD. R848 can also reshape the TME by polarizing immunosuppressive tumor-associated macrophages from the tumor-supporting M2 phenotype to the tumor-eradicating M1 phenotype. However, their clinical application is often hindered by their poor bioavailability. In addition, the clinical research of most TLR immunomodulators limits the distribution of drugs in hard-to-reach tumors, hindering their clinical application. Through the precise delivery of a nano-drug delivery system, PDT and ICD synergistically promote a stronger immune response, which is a promising way to solve the current limitation of single drug immune response SUMMARY
[0004] To solve the problems of the prior art, the present application provides a kind of intelligent nano-regulator for the photodynamic therapy of tumor. The nano-regulator (TCF-PR848 NPs) is modified by side chain modified pH-sensitive immunoadjuvant R848, and the polyethylene glycol polycarbonate amphiphilic polymer with biotin (Biotin) introduced at the end of polyethylene glycol is co-assembled with small molecule photosensitizer Tcy5-Ph-3F. Under light, TCy-Ph-3F can effectively guide endoplasmic reticulum stress, promote the release of immune damage-associated molecular patterns (DAMPs), and induce immune response. At the same time, due to the micro-acidic environment of TME, the hydrolysis of R848 is promoted, and the maturation of DC cells is promoted. The two synergistically work together to achieve a stronger immune response and ensure a more long-term and effective tumor suppression performance.
[0005] The technical scheme adopted by the present application is: a preparation method of a nano-regulator, comprising the following steps:
[0006]
[0007] (1) The substrate MV, N,N'-carbonyldiimidazole (CDI), and acetic acid (Hac) are added to MeCN for reaction, wherein the molar ratio of the substrate MV, N,N'-carbonyldiimidazole (CDI), and acetic acid (Hac) is 1: (1-3): (10-20); after the reaction is completed, cooling, rotary evaporation, extraction, and column chromatography purification are performed to obtain white solid TMV;
[0008] (2) In a nitrogen-filled glove box, Botin-PEG, TMV, thiourea (TU), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) are added to THF, stirred and reacted, precipitated with ether, and after centrifugation, the solid is collected to obtain PEG-b-PTMV;
[0009] The molar ratio of Botin-PEG, TMV, TU, DBU is 1: (2-4): (1-2): 1;
[0010] (3) PEG-b-PTMV and R848 are dissolved in anhydrous ethanol, and the reaction is stirred; after the reaction is completed, the ethanol is removed under reduced pressure, and the crude product is dissolved in THF; after dialysis, freeze-drying is performed to obtain PEG-b-PR848;
[0011] (4) The polymer PEG-b-PR848 and the photosensitizer TCy5-Ph-3F are dissolved in DMF at a mass ratio of (5-15): 1, and ultrasonic treatment is performed; then dialysis is performed in ultrapure water to obtain a nano-regulator.
[0012] Further, in the step (1), the reaction condition is to react at 70℃-0℃ for 2-4h, and extraction is performed using ethyl acetate and hydrochloric acid aqueous solution, and the concentration of the hydrochloric acid aqueous solution is 1 M.
[0013] Further, in the step (2), the reaction condition is to stir at 25℃-35℃ for 20h-30h.
[0014] Further, in the step (3), the reaction condition is to react at 70℃-90℃ for 10-15h;
[0015] The dialysis process is: dialysis is performed using distilled deionized water for 20h-24h, and the molecular weight cut-off is 3500 Da.
[0016] Further, in the step (4), ultrasonic treatment is performed at 300W for 8-15 minutes; the dialysis process is: dialysis is performed in ultrapure water for 20h-24h, and the ultrapure water is replaced every 5-6 hours, and a regenerated cellulose dialysis bag with a molecular weight cut-off of 3500 Da is used.
[0017] Further, in the step (1), the molar ratio of MV, CDI, Hac is 1:1.5:18;
[0018] The molar ratio of Botin-PEG, TMV, TU, DBU in the step (2) is 1:3:1.5:1;
[0019] The molar ratio of PEG-b-PTMV to R848 in the step (3) is 1:5;
[0020] The mass ratio of PEG-b-PR848 to TCy5-Ph-3F in the step (4) is 10:1.
[0021] A nano-regulator is prepared by the above preparation method.
[0022] Use of nanoregulator in the preparation of a medicament for treating lung tumor or breast tumor.
[0023] Further, the drug targets the endoplasmic reticulum of tumor cells.
[0024] Further, the nanoregulator is used in the preparation of a preparation for promoting the maturation of dendritic cells.
[0025] Specifically, an intelligent nanoregulator applied to tumor photoimmunotherapy, wherein the required nanocarrier and photosensitizer have the following molecular structural formula:
[0026]
[0027] wherein the small molecule photosensitizer TCy5-Ph-3F is a disclosed compound.
[0028] The present application also provides a preparation method of the nanocarrier and photosensitizer, comprising the following steps:
[0029] (1) MV, CDI, and Hac are added to MeCN and stirred at 75℃ for 3 h. After the reaction is completed, the mixture is cooled to room temperature and rotary evaporated. The crude residue after rotary evaporation is extracted with ethyl acetate and hydrochloric acid aqueous solution. The organic phase is filtered, concentrated, and purified on a silica gel column with ethyl acetate: petroleum ether to obtain the required white solid TMV.
[0030] (2) In a nitrogen-filled glove box, Botin-PEG, TMV, TU, and DBU are added to THF and stirred at 30℃ for 24 h. The reaction is precipitated with diethyl ether, and the solid is collected after centrifugation to obtain PEG-b-PTMV.
[0031] (3) PEG-b-PTMV and R848 are dissolved in anhydrous ethanol and stirred at 80℃ for 12 h. After the reaction is completed, ethanol is removed under reduced pressure, and the crude product is dissolved in THF. Dialysis is performed with distilled water (MWCO = 3500) for 24 h, and freeze-drying is performed to obtain PEG-b-PR848.
[0032] (4) 2-methylbenzothiazole was first stirred and dissolved in acetonitrile at room temperature with benzyl bromide. Then the reaction was heated to 60°C for 24 hours. After that, the reaction mixture was cooled to room temperature. The precipitate was filtered and dried under vacuum to obtain compound 2. POCl3 was dropped into DMF and stirred in an ice water bath for 1 hour. After that, the mixture was stirred at room temperature for three hours. Then, 2-(4-(trifluoromethyl)phenyl)acetic acid was added to the mixture. The clear solution was heated to 90°C for 4 hours, and then the reaction mixture was cooled to room temperature. Crushed ice was added to the dark mixture, and then a saturated sodium chloride solution was added. The obtained solid was filtered, and washed carefully with a saturated sodium chloride solution twice to obtain an intermediate product, which was used in the next step without further purification. The intermediate product was added to a NaOH solution, and heated to stir at 90°C until dissolution. The reaction mixture was cooled to room temperature and diluted with water. The solution was acidified to pH = 2 with a 10% hydrochloric acid solution to form compound 1. Compound 1 and 2 were added to ethanol and stirred, and 3 drops of pyridine were added. The obtained solution was heated to reflux, and monitored by TLC analysis. After the intermediate yellow substance was significantly reduced, the solvent was evaporated under reduced pressure to obtain a residue. The raw material was adsorbed on silica gel and purified by column chromatography to obtain the corresponding compound TCy5-Ph-3F.
[0033] (5) The polymer PEG-b-PR848 and TCy5-Ph-3F were dissolved in DMF, and the solution was gradually introduced into ultrapure water while being treated with 300 W ultrasound. The obtained dispersion was further treated with ultrasound for 10 minutes, and then dialyzed in ultrapure water for 24 hours to eliminate organic solvents. During the dialysis process, the ultrapure water was replaced every 6 hours, and regenerated cellulose dialysis bags with a molecular weight of 3500 Da were used. Finally, the solution taken out of the dialysis bag constituted a stock solution of (TCF-PR848 NPs), which was then stored at 4°C. The comparative nano TCF-PTMV NPs were prepared by referring to the same method.
[0034] Further, the molar ratio of MV, CDI, Hac in step (1) is 1:1.5:18; the concentration of hydrochloric acid in the hydrochloric acid aqueous solution is 1 M;
[0035] Further, the molar ratio of Botin-PEG, TMV, TU, DBU in step (2) is 1:3:1.5:1;
[0036] Further, the molar ratio of PEG-b-PTMV and R848 in step (3) is 1:5;
[0037] Further, the molar ratio of compound 1 and compound 2 in step (4) is 1:2;
[0038] Further, the mass ratio of PEG-b-PR848 / PEG-b-PTMV to TCy5-Ph-3F in the step (5) is 10:1.
[0039] Further, the application of the nano-regulator in the preparation of anti-tumor therapeutic drugs.
[0040] The nano-regulator has tumor targeting and tumor micro-acid environment response drug release capabilities.
[0041] The nano-regulator improves the active oxygen production capacity of the photosensitizer.
[0042] The nano-regulator causes endoplasmic reticulum stress and promotes the release of immune damage-related molecular patterns.
[0043] The nano-regulator can promote the maturation of dendritic cells (DCs).
[0044] The present application provides a kind of intelligent nano-regulator for the photoimmunotherapy of tumor.The nano-regulator (TCF-PR848 NPs) is modified by side chain modified pH-sensitive R848, and the polyethylene glycol end is introduced into the polyethylene glycol polycarbonate amphiphilic polymer with small molecule photosensitizer TCy5-Ph-3F Co-assembly is formed.The nano-regulator has good tumor targeting effect after intravenous injection, and TCy-Ph-3F can effectively guide endoplasmic reticulum stress under light, promote the release of DAMPs, and induce immune response.At the same time, due to the micro-acid environment of TME, promote the hydrolysis of R848 infiltration, promote the maturation of DC cells.Both synergies, higher DCs maturation is achieved in immune experiment, realize stronger immune response, ensure more long-term effective antitumor performance.
[0045] Compared with the prior art, the present application has the following characteristics and advantages:
[0046] (1) high tumor targeting: the nano-regulator has active targeting ability due to the modification of biotin on the surface of the polymer, and has better tumor targeting effect;
[0047] (2) high active oxygen yield: the photosensitizer inside the nano-regulator has slight aggregation phenomenon, and has better active oxygen and superoxide anion radical production capacity under the same photosensitizer concentration.
[0048] (3) can cause endoplasmic reticulum stress: the nano-photosensitizer is located in the endoplasmic reticulum, and active oxygen is produced under light to trigger endoplasmic reticulum stress and promote the release of immune damage-related molecular patterns.
[0049] (4) high tumor targeting: the nano-regulator can effectively target solid tumors after intravenous injection.
[0050] (5) Acid-activated drug release ability: The intelligent nanoregulator can be acid-responsive to release the immunoadjuvant R848 under the tumor micro-acidic environment.
[0051] (6) Promote dendritic cell maturation: On the one hand, the release of immune damage-related molecular patterns promotes dendritic cell maturation, and on the other hand, the tumor micro-acidic environment hydrolyzes the released R848 to promote dendritic cell maturation. Both synergistically make the dendritic cell maturation significantly higher than a single component, making the host have better tumor immunity. BRIEF DESCRIPTION OF DRAWINGS
[0052] Figure 1 is the absorption and emission spectrum of the nanoregulator TCF-PR848 NPs and the small molecule photosensitizer Tcy5-Ph-3F under the same photosensitizer concentration.
[0053] Figure 2 is the particle size and nanostability test of the nanoregulator TCF-PR848 NPs.
[0054] Figure 3 is the reactive oxygen species enhancement experiment test of the nanoregulator TCF-PR848 NPs.
[0055] Figure 4 is the tumor micro-acidic environment-responsive release of R848 test of the nanoregulator TCF-PR848 NPs.
[0056] Figure 5 is the cell uptake test of the nanoregulator TCF-PR848 NPs.
[0057] Figure 6 is the subcellular organelle distribution image of the nanoregulator TCF-PR848 NPs.
[0058] Figure 7 is the intracellular reactive oxygen species production experiment of the nanoregulator TCF-PR848 NPs.
[0059] Figure 8 is the MTT experiment of the nanoregulator TCF-PR848 NPs.
[0060] Figure 9 is the CRT eversion experiment caused by the nanoregulator TCF-PR848 NPs.
[0061] Figure 10 is the HMGB1 migration experiment caused by the nanoregulator TCF-PR848 NPs.
[0062] Figure 11 is the MHC-Ⅱ molecule expression experiment caused by the nanoregulator TCF-PR848 NPs.
[0063] Figure 12 is the test of dendritic cell maturity caused by nano-regulator TCF-PR848 NPs.
[0064] Figure 13 is the test of tumor targeting ability of nano-regulator TCF-PR848 NPs. DETAILED DESCRIPTION
[0065] The technical solutions of the present application are further described below in combination with specific embodiments.
[0066] The ultrapure water was prepared by Milli-Q Plus system (Millipore Corporation, Bedford, USA).
[0067] Example 1
[0068] The intelligent nano-regulator (TCF-PR848 NPs) in the present application is prepared by the following method:
[0069]
[0070] (1) MV (16.3 g, 50 mmol), MeCN (80 mL) were added to a 250 ml reaction flask, and the reaction mixture was stirred at room temperature. Then N,N'-carbonyldiimidazole (CDI) (12.1 g, 75 mmol) was added, and stirred for 5 min. Finally, acetic acid (Hac) (48 mL, 800 mmol) was added, and stirred at 75°C in a preheated oil bath for 3 h. After 3 h, the mixture was removed from the oil bath and cooled to room temperature. The volatile solvent was removed by rotary evaporation. The crude residue was dissolved in ethyl acetate (100 ml) and poured into 1 M HCl (100 ml). The organic and aqueous phases were separated. The aqueous phase was extracted with ethyl acetate. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The residual hydroxyacetic acid was removed from the azeotrope with toluene. The resulting residue was purified by chromatography on a silica gel column with ethyl acetate: petroleum ether (1:1, v / v) to obtain the desired white solid TMV.
[0071] (2) In a glove box filled with nitrogen, Botin-PEG (0.2157 g, 0.01 mmol), TMV (1.056 g, 3.0 mmol), and Thiourea (TU) (55 mg, 0.15 mmol) were added into a 50 mL round bottom flask. Then 6 mL THF (0.5 M) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (15 μL, 0.10 mmol) were added, and stirred at 30 °C for 24 h, precipitated with ether, and the solid was collected after centrifugation. This process was repeated twice to obtain PEG-b-PTMV.
[0072] (3) PEG-b-PTMV and R848 were dissolved in anhydrous ethanol (10 mL) at a molar ratio of 1:5 and added into a flask (100 mL). The reaction was stirred at 80 °C for 12 h. After the reaction was completed, the ethanol was removed under reduced pressure, and the crude product was dissolved in 5 mL THF. Dialysis was performed using distilled water for 24 h (MWCO = 3500), and then freeze-drying was performed to obtain PEG-b-PR848.
[0073] (4) 2-Methylbenzothiazole (4 g, 26.8 mmol) was stirred in acetonitrile (10 mL) and benzyl bromide (3 g, 17.5 mmol) was added at room temperature. The reaction was heated to 60 °C for 24 hours. Subsequently, the reaction mixture was cooled to room temperature. The precipitate was filtered and dried under vacuum to obtain compound 2. POCl3 (2.1 mL, 22.5 mmol) was added dropwise into DMF (9 mL) and stirred in an ice water bath for 1 hour. Thereafter, the mixture was stirred at room temperature for three hours. Subsequently, 2-(4-(trifluoromethyl)phenyl)acetic acid (1 g) was added to the mixture. The clear solution was heated to 90 °C for 4 hours, and then the reaction mixture was cooled to room temperature. Crushed ice was added to the dark mixture, followed by the addition of a saturated sodium chloride solution. The resulting solid was filtered, and carefully washed twice with a saturated sodium chloride solution to obtain an intermediate product, which was used in the next step without further purification. The intermediate product was added to a 10 mL NaOH (0.4 g, 10 mmol) solution and heated to stir at 90 °C until dissolved. The reaction mixture was cooled to room temperature and diluted with 10 mL water. The solution was acidified to pH = 2 with a 10% hydrochloric acid solution to form compound 1. Compound 1 and 2 were stirred in ethanol (10 mL) at a molar ratio of 1:2, and 3 drops of pyridine were added. The resulting solution was heated to reflux, and monitored by TLC analysis. After the intermediate yellow substance was significantly reduced, the solvent was evaporated under reduced pressure to obtain a residue. The raw material was adsorbed on silica gel and purified by column chromatography to obtain the corresponding compound TCy5-Ph-3F.
[0074] (5) Polymer PEG-b-PR848 and TCy5-Ph-3F were dissolved in DMF at a mass ratio of 10:1, and the solution was gradually introduced into ultrapure water while being treated with 300 W ultrasound. The obtained dispersion was further treated with ultrasound for 10 minutes, and then dialyzed in ultrapure water for 24 hours to eliminate the organic solvent. During the dialysis process, the ultrapure water was replaced every 6 hours, and regenerated cellulose dialysis bags with a molecular weight of 3500 Da were used. Finally, the solution taken out of the dialysis bag constituted the stock solution of (TCF-PR848 NPs), which was then stored at 4°C.
[0075] The comparative nano-TCF-PTMV NPs were prepared by the same method as described above, steps (3) and (4) were omitted, and PEG-b-PTMV prepared in step (2) was directly subjected to the operation of step (5).
[0076] Example 2: Absorption and emission spectrum test of nano-regulator TCF-PR848 NPs
[0077] A 3ml TCF-PR848 NPs solution was configured, the test temperature was 25°C, the test range was 200-800nm, and the fluorescence emission spectrum test range was 670-800nm. Figure 1 (a) is the absorption spectrum; (b) is the emission spectrum.
[0078] Example 3: Nanoparticle size and stability test of nano-regulator TCF-PR848 NPs
[0079] The hydration particle size and nano-stability of the nanoparticles were measured by a dynamic light scattering particle size analyzer (DLS). Figure 2 (a) is the nanoparticle size; (b) is the nano-stability, wherein the nanoparticle size is about 148 nm and has good stability.
[0080] Example 4: Determination of active oxygen generation performance of nano-regulator TCF-PR848 NPs
[0081] 2',7'-dichlorofluorescein hydrogen (DCF) was selected as the active oxygen monitoring probe, and dihydro rhodamine 123 (DHR123) was selected as the superoxide anion detection probe. Under the same photosensitizer concentration and light intensity (660 nm, 5 mW / cm 2 ), the fluorescence increase degrees of DCF and DHR123 in different treatment groups (TCF-PR848 NPs and TCy5-Ph-3F) were detected, respectively. Figure 3 It can be seen that the fluorescence increase degrees of DCF and DHR123 in the TCF-PR848 NPs group are greater, indicating that the nano-regulator TCF-PR848 NPs has a higher active oxygen generation capacity.
[0082] Example 5: Acid-responsive release of R848 from nano-regulator TCF-PR848 NPs test
[0083] A certain amount of TCF-PR848 NPs mother liquor was placed in pH 7.4, pH 6.8 buffer solution for a period of time. Then separated by high performance liquid chromatography, and compared with small molecule spectrum. It can be seen that Figure 4 TCF-PR848 NPs can achieve the release of small molecule immunoadjuvant R848 at pH 6.8.
[0084] Example 6: Cell uptake experiment of nano-regulator TCF-PR848 NPs
[0085] MCF-7 cells were seeded in confocal dishes at a density of 1 × 10 5 / mL overnight. Fresh culture medium containing 25 μg mL -1 TCF-PR848 NPs was used to replace. After the cells were incubated with the nano-regulator-containing medium for different times, live cell images were taken using a confocal laser scanning microscope (CLSM, Ex / Em = 660 / 710 nm). It can be seen that Figure 5 The nano-regulator enters the cells around 2 h, and reaches the maximum uptake level around 6 h.
[0086] Example 7: Subcellular organelle distribution image of nano-regulator TCF-PR848 NPs
[0087] MCF-7 cells were cultured in confocal dishes for 24 h, then 25 μg mL -1 TCF-PR848 NPs were added, and cultured under standard conditions for 4 h, then the culture medium was removed and washed twice with PBS. Commercial localization probes Lyso Tracker (Ex / Em = 443 / 505 nm), Mito Tracker (Ex / Em = 490 / 516 nm), ER Tracker (Ex / Em = 504 / 511 nm) and Hoechst (Ex / Em = 340 / 510 nm) were added, and the cells were incubated for a specified time, washed twice with PBS before imaging, and the localization and fluorescence intensity of each group were observed using CLSM. It can be seen that Figure 6 TCF-PR848 NPs are mainly distributed in the endoplasmic reticulum.
[0088] Example 8: Intracellular reactive oxygen species detection of nano-regulator TCF-PR848 NPs
[0089] The generation of ROS in MCF-7 cells was detected using the specific fluorescent probe 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), and the generation of superoxide anion free radicals in MCF-7 cells was detected using the specific fluorescent probe dihydroethidium (DHE). MCF-7 cells were seeded in confocal dishes at a density of 1 x 10 5 cells per well and incubated for 24 h. Different treatments were performed in each well, including a blank control, light (660 nm, 5 mW / cm 2 ). After washing three times with PBS, the cell morphology was observed using CLSM. As shown in FIG. 2, (a) is a DCF fluorescence image, and (b) is a DHR123 image. Compared with the control group, both TCF-PR848 NPs and the comparative nano TCF-PTMV NPs can significantly induce an active oxygen burst in cells. Figure 7
[0090] Example 9: Toxicity experiment of nano-regulator TCF-PR848 NPs
[0091] MCF-7 cells were seeded in 96-well plates at a density of 1 x 10 5 cells per well and incubated at 37°C under 21% O2 for 24 h. Then, nano-regulator TCF-PR848 NPs and comparative nano TCF-PTMV NPs were added to the culture medium at concentrations of 0-45 μg / mL, and the light toxicity group was irradiated (660 nm, 5 mW / cm 2 , 10 min) after incubation under normoxic conditions for 6 h, and incubation was continued for 24 h. Subsequently, 100 μL of MTT solution was added to each well, and incubation was continued under the same conditions for another 4 h. The MTT solution was removed, and 100 μL of DMSO was added to each well. Subsequently, the absorbance at 570 nm and 630 nm was determined on a microplate reader, and the cell survival rate was calculated using the following formula
[0092]
[0093] OD sam570 and OD sam630 represent the absorbance at 570 nm and 630 nm of the wells to which the photosensitizer was added, and OD control570 and OD sam630 represent the absorbance at 570 nm and 630 nm of the control group. The experiment was performed in quintuplicate. The same experimental procedure was performed on A549 cells and 4T1 cells to evaluate cell viability. As shown in FIG. 3, TCF-PR848 NPs have a significant killing effect on various tumor cells (A549, MCF-7, and 4T1 cells). Figure 8
[0094] Example 10: Nanoregulator TCF-PR848 NPs induced CRT evert experiment
[0095] Calreticulin (CRT) is a highly conserved endoplasmic reticulum Ca 2+ binding chaperone, in addition to maintaining intracellular Ca 2+ balance and responsible for the folding of glycoproteins, also involved in mitochondrial metabolism, gene expression and apoptosis. Endoplasmic reticulum stress caused by tumor cells can lead to CRT evert in tumor cells. Everted CRT can effectively enhance the recognition and phagocytosis of tumor cells by antigen-presenting cells, thereby triggering the immune killing effect of the same tumor cells, which is a key factor for tumor cell immunogenic apoptosis. In this experiment, immunofluorescence staining method was used to detect the CRT evert phenomenon in cells under different treatments.
[0096] Operation method: MCF-7 cells were cultured in confocal dishes for 24 h, then incubated with 20 μg mL -1 of TCF-PR848 NPs culture solution for 4 h, and then light (660 nm, 5 Mw cm -2 , 5 min) and dark treatment, and then cultured in a cell incubator for 2 h. Then fixed with immunostaining fixative. After fixation, wash twice with immunostaining washing solution. Then add immunostaining blocking solution, 4°C blocking overnight. According to the instructions, dilute CRT primary antibody with immunostaining primary antibody diluent at an appropriate ratio. After removing the blocking solution, wash twice with washing solution, then add the diluted primary antibody, 4°C room temperature, slowly shake on the shaker for 1 h. Recover the primary antibody, wash with immunostaining washing solution for 5 minutes, 3 times. According to the instructions of the secondary antibody, dilute the fluorescein-labeled secondary antibody with immunofluorescence staining secondary antibody diluent at an appropriate ratio, and incubate the washed cells with the secondary antibody working solution on the shaker at room temperature for 1 h. Recover the secondary antibody, wash 3 times with washing solution, each for 5 minutes. Stain the cell nucleus with DAPI. After staining, use CLSM to perform multi-color imaging of the cells. DAPI (Ex / Em=350 nm / 460 nm). It can be seen that TCF-PR848 NPs induced MCF-7 CRT evert to the greatest extent. Figure 9
[0097] Example 11: Nanoregulator TCF-PR848 NPs induced HMGB1 migration experiment
[0098] High mobility group box-1 protein (HMGB1) is a non-histone chromosomal binding protein present in the nucleus of eukaryotic cells. Under normal circumstances, HMGB1 is mainly located in the nucleus and acts as a chaperone for DNA and chromatin binding, but it can also shuttle from the nucleus to the cytoplasm under various stress conditions. After cell damage, HMGB1 is passively released as an important molecule of damage-associated molecular patterns (DAPMs), which can promote the maturation of dendritic cells (DCs) and in turn activate cytotoxic T cells (CTLs), prompting CTLs to kill tumor cells. In this experiment, immunofluorescence staining was used to detect HMGB1 in cells under different treatments. The operation method was the same as the detection of CRT, and the first antibody was HMGB1 rabbit polyclonal antibody (HMGB1 Rabbit Polyclonal Antibody). Figure 10 It can be seen that the brightness of HMGB1 in the nucleus of the TCF-PR848 NPs treatment group is the lowest, and the migration degree is the largest.
[0099] Example 12: Tumor targeting experiment of nanoregulator TCF-PR848 NPs
[0100] The distribution of TCF-PR848 NPs in 4T1 tumor-bearing mice was determined using a small animal imaging instrument. After tail vein injection of 100 μL CF-PR848 NPs (2.5 mg / mL), optical imaging of the whole body of anesthetized mice was performed at different time points (Ex / Em = 660 / 710 nm) using an imaging system (IVIS Lumina imaging system). Figure 13 It can be seen that TCF-PR848 NPs can effectively target the tumor area.
[0101] Example 13: Detection of dendritic cell maturation induced by nanoregulator TCF-PR848 NPs (MHC-Ⅱ, CD80, CD86 molecule expression) experiment
[0102] First, DC2.4s were cultured at 1.5 × 10 5DCs were seeded in 12-well plates at a density of 1.5 x 105cells / well. After 24 h, 4T1 cells pretreated by different methods were added to the DCs in the plates for co-incubation. After 24 h of stimulation and activation at 37 °C in a 5 % CO2 environment, the DCs were washed and digested into 1.5 mL centrifuge tubes, and resuspended with 100 μL PBS buffer. 0.5 μL of MHC II (PE / Cy7), CD80 (APC), and CD86 (APC / Cy7) flow cytometry antibodies were added to the centrifuge tubes, which were vortexed for 10 s, and then incubated at 4 °C in the dark for 40 min, during which the working solution was vortexed every 10 min. After staining, the DCs were washed and centrifuged twice to remove unbound antibodies, and finally diluted with 300 μL of PBS solution for flow cytometry analysis. Figure 11 and 12 In the above, the six groups are: G1 (Control), G2 (Control+Light), G3 (TCF-PTMV NPs), G4 (TCF-PTMV NPs+Light), G5 (TCF-PR848 NPs), and G6 (TCF-PR848 NPs+Light). It can be seen from Figure 11 that the expression degree of MHC-Ⅱ molecules in the G6-TCF-PR848 NPs treatment group is the largest. It can be seen from Figure 12 that the maturity of DCs cells in the G6-TCF-PR848 NPs treatment group is the largest, indicating that TCF-PR848 NPs can effectively cause an immune burst, and thus enable the host to obtain stronger immune capacity.
[0103] The above describes only the preferred specific embodiments of the present application, but the protection scope of the present application is not limited thereto, and any person skilled in the art can make equivalent replacements or changes to the technical solutions and inventive concepts of the present application within the technical range disclosed by the present application, which should be covered within the protection scope of the present application. It should be understood by those skilled in the art that any improvement, equivalent replacement of the selected materials, and replacement and selection of auxiliary ingredients of the present application, etc., fall within the protection scope and disclosure range of the present application.
Claims
1. A method of preparing a nanoregulator, characterized by, The method comprises the following steps: ; (1) adding a substrate MV, N,N'-carbonyldiimidazole and acetic acid into MeCN for reaction, wherein the molar ratio of the substrate MV, N,N'-carbonyldiimidazole and acetic acid is 1:(1-3):(10-20); after the reaction is completed, cooling, rotary evaporation, extraction and column chromatography purification are performed to obtain a white solid TMV; (2) in a glove box filled with nitrogen, Botin-PEG, TMV, thiourea and 1,8-diazabicyclo[5.4.0]undec-7-ene are added into THF for stirring reaction, precipitation with ether, centrifugation and collection of the solid to obtain PEG-b-PTMV; the molar ratio of the Botin-PEG, TMV, thiourea and 1,8-diazabicyclo[5.4.0]undec-7-ene is 1:(2-4):(1-2):1; (3) PEG-b-PTMV and R848 are dissolved in anhydrous ethanol for stirring reaction; after the reaction is completed, ethanol is removed under reduced pressure, and the crude product is dissolved in THF; dialysis and freeze-drying are performed to obtain PEG-b-PR848; (4) the polymer PEG-b-PR848 and a photosensitizer TCy5-Ph-3F are dissolved in DMF at a mass ratio of (5-15):1, and ultrasonic treatment is performed; then dialysis is performed in ultrapure water to obtain a nano-regulator.
2. The method of claim 1, wherein: In the step (1), the reaction condition is 2-4 h at 70-0 DEG C, and the extraction is performed with ethyl acetate and hydrochloric acid aqueous solution, and the concentration of the hydrochloric acid aqueous solution is 1 M.
3. The method of claim 1, wherein: In the step (2), the reaction condition is stirring for 20-30 h at 25-35 DEG C.
4. The method of claim 1, wherein: In the step (3), the reaction condition is 10-15 h at 70-90 DEG C; The dialysis process is: dialysis for 20-24 h with distillated deionized water, and the molecular weight cut-off is 3500 Da.
5. The method of claim 1, wherein: In the step (4), the ultrasonic treatment is performed for 8-15 min at 300 W; the dialysis process is: dialysis for 20-24 h in ultrapure water, and the ultrapure water is replaced every 5-6 h, and regenerated cellulose dialysis bags with a molecular weight cut-off of 3500 Da are used.
6. The preparation method according to claim 1, wherein: in the step (1), the molar ratio of the substrate MV, N,N'-carbonyldiimidazole and acetic acid is 1:1.5:18; in the step (2), the molar ratio of the Botin-PEG, TMV, thiourea and 1,8-diazabicyclo[5.4.0]undec-7-ene is 1:3:1.5:1; in the step (3), the molar ratio of PEG-b-PTMV and R848 is 1:5; in the step (4), the mass ratio of PEG-b-PR848 and TCy5-Ph-3F is 10:
1.
7. A nanoregulator characterized by: The preparation method is prepared according to any one of claims 1-6.
8. The use of a nanoregulator according to claim 7, characterized in that: The nano-regulator is used for preparing a drug for treating lung tumors or breast tumors.
9. The use of a nanoregulator according to claim 8, characterized in that: The drug targets the endoplasmic reticulum of tumor cells.
10. The use of a nanoregulator according to claim 7, characterized in that: The nano-regulator is used for preparing a preparation for promoting the maturation of dendritic cells.
